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Rheumatoid arthritis is related to increase of 
mortality and decrease of life expectancy. Despite 
RA therapy development has been in advance 
level, mortality rate of RA patients remains 
high compared to general population. Higher 
mortality of RA patients is mainly caused by early-
manifested atherosclerosis of coronary artery 
and cerebrovascular which is accompanied by 
other cardiovascular complications such as heart 
failure.9 A meta-analysis concluded mortality due 
to CVD is 50% higher in RA patients compared to 
general population.10 The CARRE study reported 
RA patients have similar risk of CVD to diabetic 
patients. This study found prevalence of CVD of 
5% in non-diabetic and  non-RA patients, 12.4% 
in type 2 DM patients, and 12.9% in RA patients.11 
Lindharsen reported risk of myocardial infarction 
in RA patients is similar to diabetic patients.12 
Mechanism  of increased mortality  caused by 
CVD in RA patients is thought to start very early 
in pathogenesis of the disease. Thus, it is important 
for medical doctor to understand the treatment 
strategy of CVD in RA patients in order to increase 
treatment quality.  
PATHOGENESIS OF CARDIOVASCULAR DISEASE 
IN RHEUMATOID ARTHRITIS
The exact mechanism lies on the relation of RA and 
CVD is not yet fully known. Higher prevalence of 
traditional risk factors can explain some parts of it, 
but evidence from prospective cohort study found 
risk of CVD in RA patients remains constant after 
adjustment of those traditional risk factors.14
Infl ammation is thought to be another 
pathophysiologic pathway causing higher 
cardiovascular risk in RA patients. Infl ammatory 
mediators in circulation can affect arterial wall 
where these mediators play role in every stage 
of atherosclerosis,  starts from endothelial 
dysfunction, plaque formation, until plaque rupture. 
The similarity of infl ammatory and immunologic 
response between RA and atherosclerosis has been 
revealed in recent years. Earlier atherosclerosis 
is suggested  as a result of interaction between 
traditional CVD risk factors in RA patients and 
newly risk factors, mainly systemic infl ammation.15 
It is summarized in fi gure 1 and table 1.  
ABSTRACT
Despite rheumatoid arthritis (RA) therapy development 
has been in advance level today, its  mortality remains 
increasing in general population. The mortality is mainly 
caused by early-manifested atherosclerosis and other 
cardiovascular complications. Available evidences show 
this condition appears in early stage of the disease. 
Thus, early detection and management of cardiovascular 
risk, followed by control of these factors are necessary 
to reduce morbidity and mortality of RA patients. 
Cardiovascular disease (CVD) is a common cause 
of death, with higher number than cancer, chronic 
lower respiratory tract disease, and accident. It 
is estimated that 81,100,000 adults (more than 
a third) in US have one or more CVD. Everyday 
2,300 patients die because of CVD which means 
one death in every 38 seconds.1 Cardiovascular 
disease is the main cause of death in UK. Every 
year 191,000 patients die (1 of 3 deaths) because 
of the disease.2 In Indonesia, 59.5% deaths caused 
by non-communicable diseases such as stroke 
(15.4%), hypertension (6.8%), diabetes mellitus 
(DM) (5.7%) , and ischemic heart disease (5.1%).3
It has been known that traditional risk factors 
such as hypertension, smoking, and physical 
inactivity are the main contributors to atherogenesis. 
Recently, it is proposed that infl ammation may 
have a role in atherogenesis. The importance of 
infl ammation in the pathogenesis of atherosclerotic 
CVD is supported by fi ndings of higher prevalence 
of  CVD in diseases related to systemic infl ammation 
such as psoriasis, periodontitis, hypertension, DM, 
and rheumatoid arthritis (RA).4  
Rheumatoid arthritis is the most common 
infl ammatory arthritis which found in 0.5-1% adult 
population. Prevalence in female is twice higher 
than male. Prevalence becomes higher in older 
population  and mostly found in female aged more 
than 65 years. It is reported that incidence of RA 
is approximately 5-50 per 100,000 every year.5,6 
An epidemiological study reported RA prevalence 
of 0.3% in Central Java.7 Although etiology of 
RA is yet unknown, many studies suggested that 
combination of genetic and environmental factor 
plays role. Genes predisposing to RA are HLA-
DRB1, PTPN22, STAT4, TRAF1/C5, and genes 
from 6q23 region.8
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Table 1 Atherogenesis in rheumatoid arthritis: traditional risk 
factors and disease-related risk factors16
Risk factors
Traditional Age, smoking, dyslipidemia, insulin resistance /
diabetes mellitus, hypertension, physical inactivity, 
obesity 
Disease related
   Infl ammatory Proatherogenic cytokine, chemokine, increasing 
expression of  adhesion molecule, autoantibody, 
subset perturbation of  T cells, genetic 
polymorphism, hyperhomocysteinemia, oxidative 
stress, apoptosis disorder, prothrombotic variable 
   Non-infl ammatory  Immobilization, body weight gain 
   Iatrogenic Glucocorticoid, methotrexate, NSAIDs, COX-2 
inhibitors
NSAIDs, nonsteroidal anti-infl ammatory drugs; COX-2, cyclo-oxygenase-2
RHEUMATOID ARTHRITIS AND TRADITIONAL 
CARDIOVASCULAR RISK FACTORS
A meta-analysis reported some traditional cardiovascular risk 
factors such as smoking, DM, and low level of high density 
of lipoprotein (HDL) are more often found in RA patients.17
Smoking
A study stated that prevalence of smoking was increased in 
RA patiens with OR 1.56. Smoking can increase the risk of RA 
in seropositive patients who smoke >25 cigarettes for more 
than 20 years. Smoking is also related to RA with more severe 
manifestation. This condition may be caused by genetic and 
environmental factors. Combination of smoking and double-
copy of allele HLA-DRB1 increases risk of RA and earlier 
mortality, especially caused by CVD.17 
Diabetes
Patients with RA have higher risk to have insulin resistance. 
Disorder in glucose process occurs as a result of peripheral 
insulin resistance mediated by infl ammatory response.9 
Interleukin-6 (IL-6) is suggested to be linked to insulin 
resistance in human.18,19 Inhibition of IL-6 is shown to 
reduce risk of insulin resistance in RA patients.20 Some 
studies reported no signifi cant difference in percentage of 
DM between RA patients and control,21,22 while other studies 
reported higher risk of DM in RA population.17,23
Use of glucocorticoid may infl uence glucose metabolism 
in RA patients. Due to the effects of chronic infl ammation 
and glucocorticoid use to glucose metabolism, it is diffi cult to 
consider that increasing prevalence of DM is caused only by 
RA.17 However, Hoes reported no difference in risk of insulin 
resistance  between RA patients who consumed and did not 
consume steroid.24 
Blood Pressure
Prevalence of hypertension in RA patients varied from 3.8 to 
73%.25 A meta-analysis reported no signifi cant difference in 
blood pressure betweeen RA patients and general population.17 
A 10 year follow-up cohort study in 325 RA patients concluded 
that hypertension increases cardiovascular events risk (hazard 
ratio 3.76; 95% CI 0.99-15.06).26
Dyslipidemia
Dyslipidemia is found in 55-65% RA patients.27 Dyslipidemia 
in RA is related to activity of infl ammatory disease. 
Higher disease activity is related to lower level of total 
cholesterol, especially HDL. This condition occurs because 
proinfl ammatory cytokines—mainly tumor necrosis factor α 
(TNF-α)15—increase serum triglyceride (TG) level and decrease 
level of HDL.28 Level of HDL in RA patients is lower than 
general population, but prevalence of hypercholesterolemia is 
not different in both groups.17 Furthermore, RA patients have 
HDL dysfunction which causes HDL cannot prevent oxidation 
of low density lipoprotein (LDL).29,30 Therapy can improve 
lipid profi le, especially HDL which further can improve 
atherogenic index. 
Proinfl ammatory cytokines can be mediator for rheumatoid 
cachexia, a condition  where skeletal muscle is wasted and 
fat mass increases progressively. Consequently, RA patients 
have higher percentage of body fat compared to control group 
although body mass index (BMI) are similar. Furthermore, 
higher body fat mass contributes to CVD.15 Cachexic patients 
have higher total cholesterol and LDL level, and also higher 
frequency of hypertension and metabolic syndrome compared 
to RA patients without rheumatoid cachexia.31
Drugs:
NSAIDs, COX-2 inhibitor, 
glucocorticoid, DMARDs
Traditional Risk Factors:
smoking, hypertension, 
dyslipidemia, DM/insulin 
resistance
Vascular and 
morphologic function
Cardiovascular 
disease
RA Characteristics :
RA phenotype
Extra-articular diseases, RhF+, 
anti-CCP, RA severity
Genetic predisposition
Figure 1 Pathways leading to 
cardiovascular disease in rheumatoid 
arthritis patients showing role of 
traditional risk factors15
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Physical Inactivity
Although it is not included in absolute risk estimation of CVD, 
this factor has been linked to higher risk of CVD in general 
population. Physical inactivity in RA patients occurs when 
disease becomes uncontrolled and/or chronic joint damage 
leading to disability, pain, and stiffness.   
Waist circumference and higher BMI in RA patients may 
be also related to physical inactivity. However, no consistent 
fi ndings in literature explaining BMI in RA patients. It is 
possible that patients with RA are reported having higher, 
similar, or lower BMI compared to general population. In 
relation to CVD, available evidences indicate patients with low 
BMI (<20 kg/m2) have higher cardiovascular risk. Possibly it 
is  related to severity of RA because systemic infl ammation 
often causes decrease of body weight.21
RHEUMATOID ARTHRITIS AND NON-TRADITIONAL RISK 
FACTORS
Increasing risk of CVD and its mortality in RA patients which 
cannot be explained by traditional risk factors have been 
reported in literature. 
Infl ammation
It is thought that systemic infl ammation, like in RA, has 
important role in premature atherosclerosis. Proinfl ammatory 
cytokines are trigger for expression of cellular adhesion 
molecule in endothelial cells, and also can induce atherogenic 
changes including dyslipidemia, insulin resistance, oxidative 
stress, and prothrombotic state.16 Potential infl ammatory 
mechanisms leading to vascular damage are: (a) endothelial 
dysfunction via excessive nitric oxide production; (b) 
activation of coagulation cascade; and (c) induction 
of secondary dyslipidemia with atherogenic profi le.15 
Endothelial dysfunction causes change in its permeability 
and increases adhesion of leucocytes and thrombocytes. 
Furthermore, infi ltration of  T-cell and macrophage to arterial 
wall and release of infl ammatory mediators induce chronic 
infl ammation and progressive atherosclerosis.  
Systemic cytokines response activates immune cells and 
causes phenotypical  perturbation and functional subset of 
T-cell. Increasing level of CD4+CD28null T-cell is common in 
RA patients, which is autoreactive and can induce cytotoxicity 
of endothelial cells. Increasing subset of T-cells also can be 
found in patients with acute coronary syndrome and they can 
invade unstable atherosclerotic plaque.16
Genetic Infl uence
Cardiovascular disease in RA is suggested to be infl uenced by 
genetic factors. Functional polymorphism related to expression 
of major histocompatibility complex (MHC) is associated 
with increase of susceptibility to RA, myocardial infarction, 
and multiple sclerosis.9 Despite status of autoantibody, allele 
of shared epitope (genotype HLA-DRB1) is associated with 
mortality in RA. Combination of shared epitope, smoking 
habit, and anti-CCP antibody will cause higher increase of 
premature death risk in RA patients. Shared epitope is also 
thought to be related to ischemic heart disease in RA with yet 
unknown mechanism.9 TRAF1/C5, STAT4, and HLA-DRB1 
may involve in regulation of lipid metabolism in RA patients.32 
Hyperhomocysteinemia
Hyperhomocysteinemia, a condition frequently found in RA 
patients, has been considered as an independent risk factor 
in atherosclerotic disease. Hyperhomocysteinemia involves 
in endothelial dysfunction, lipoprotein oxidation, and has 
prothrombotic effects.16
   
Thrombotic Marker
Prothrombotic state such as increase of fi brinogen, von 
Willebrand factor, PAI-1, and thrombocytosis in RA patients 
may play a role in cardiovascular complications.33 
RHEUMATOID VASCULITIS 
RA patients possibly can suffer from rheumatoid vasculitis. 
Generally, it is found in small and medium blood vessels, 
including coronary artery. Although it is less frequently found 
than endothelial damage caused by systemic infl ammation, 
rheumatoid vasculitis causes 2-3 times higher risk of ischemic 
heart disease in RA patients.34
EFFECTS OF RHEUMATOID ARTHRITIS THERAPY TO RISK OF 
CARDIOVASCULAR DISEASE 
Non-steroidal anti-infl ammatory drugs (NSAIDs)
NSAIDs and cyclo-oxygenase-2 (COX-2) inhibitors are 
commonly used in RA therapy. Both drugs are thought to 
be related to side effects of hypertension, congestive heart 
failure, and kidney disorder.35 Compared to placebo, COX-2 
inhibitors group has 42% higher risk of  cardiovascular events. 
In the same study, it is concluded that compared to naproxen, 
use of COX-2 inhibitors increases risk of vascular events 
(OR 1.57, 95% CI 1.21-2.03) and myocardial infarction twice 
higher (OR 2.04, 95% CI 1.41-2.96).36 Generally, now it is 
recommended to use NSAIDs or COX-2 inhibitors with the 
lowest possible dose and the shortest possible duration. If 
NSAIDs should be used in therapy, naproxen is the drug of 
choice because cardiovascular risk of this drug seems to be 
lower than others.35 
Glucocorticoid
Glucocorticoid can induce hypertension, insulin resistance, 
blood lipid disorder, obesity, and hypercoagulability.9 
However, it is diffi cult to estimate its effect to cardiovascular 
risk in RA patients. Glucocorticoid is thought to be linked to 
cardiovascular risk, but in the other hand glucocorticoid can 
decrease disease activity and infl ammation. Until further data 
reported the effect of glucocorticoid, it is recommended to use 
it with dose as low as possible.35
Disease-modifying antirheumatic drugs (DMARDs)
a. Nonbiological DMARDs
 Methotrexate (MTX) is one of the main therapy of RA. It 
improves clinical signs of disease  and slows radiologic 
progression.35 A cohort study involving 1,240 RA patients 
reported hazard ratio of mortality in group taking MTX is 
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0.4 (95% CI 0.2-0.8).37 Use of MTX is also related to lower 
risk of metabolic syndrome.38 Ongoing Cardiovascular 
Infl ammation Reduction Trial (CIRT) study is purposed to 
observe effect of very low dose of MTX (10 mg/week) to 
cardiovascular events in general population. It is expected 
that result of this study can provide evidence to confi rm 
cardioprotective effect of MTX, as the agent is used widely 
in RA therapy.39
  Effect of other nonbiological DMARDs to CVD 
risk is yet unknown. Azathioprine, cyclosporin, and 
lefl unomide are thought to increase cardiovascular events. 
One of the reasons possibly because lefl unomide and 
cyclosporin can induce hypertension.35
b. Biological DMARDs
 In US, biological agents that have been approved today 
for RA therapy consist of TNF inhibitor (infl iximab, 
etanercept, adalimumab, certolizumab pegol, dan 
golimumab), anakinra (antagonist of IL-1 receptor), 
abatacept (CTLA4-Ig protein fusion), rituximab (anti-
CD20 antibody), and tocilizumab (antireceptor IL-6 
antibody).42
  Anti TNF-α agent is a potent drug to decrease 
infl ammation and slow radiologic progression in RA 
patients. Thus, possibly this drug can give cardiovascular 
benefi t. British Society for Rheumatology Biologics 
Register observed myocardial infarction in 8,670 RA 
patients administered with anti TNF-α agent compared 
with 2,170 RA patients treated with traditional DMARDs. 
This study did not fi nd reduction of myocardial infarction 
incidence in patients treated with anti TNF-α agent 
(hazard ratio 1.44; 95% CI 0.56-3.67). However, in group 
which gave response to therapy in six months, incidence 
of myocardial infarction was 3.5 per 1,000 patient-year 
compared to 9.4 per 1,000 patient-year in non-responsive 
group.40 Another study reported lower risk of cardiovascular 
events in group treated with TNF-α antagonist compared 
to non-biological DMARDs group.41    
  Effect of other biological agents to CVD risk is 
not known thoroughly. Anakinra, the IL-1 antagonist, 
was reported to improve vascular and left ventricular 
function in RA population.43 Rituximab was reported 
to have benefi cial effect to endothelial function and 
plasma cholesterol level. A 16 week-research involving 
fi ve RA patients treated with rituximab found decrease 
of total cholesterol and increase of HDL level.44 Use of 
tocilizumab causes slight increase of TG, LDL, and HDL 
level, but it could decrease lipoprotein (a).20 Monotherapy 
of tocilizumab could reduce arterial sclerosis. Similar 
effect were found in etanercept and adalimumab.45 The 
effect of abatacept to CVD risk is still unknown yet. 
TREATMENT
Medical treatment for RA patients including management of 
joint disease and related comorbidities such as osteoporosis, 
depression, CVD, and malignancy. These comorbidities have 
signifi cant impacts to quality of life, work disability, and 
mortality.15 Preventive strategy to decrease CVD risk in RA 
patients should be initiated immediately after diagnosis of RA 
is made. Cardiovascular evaluation in RA patients is initiated 
by detecting comorbidities such as hypertension, tobacco use, 
hyperglycemia, dyslipidemia, increased BMI, central obesity, 
physical inactivity, and family history of CVD.9
In 2010, The European League Against Rheumatism 
(EULAR) released a recommendation for treatment of 
cardiovascular risk in RA and other infl ammatory arthritis 
diseases. 
Table 3 Ten recommendations for treatment of cardiovascular risk in rheumatoid arthritis46
No. Recommendation Level of 
evidence
Strength of
recommendation
1. RA should be considered as a condition related to higher risk of CVD. Increasing risk possibly due 
to increase of traditional risk factors and infl ammatory burden
2b-3 B
2. Proper control of disease activity is necessary to reduce cardiovascular risk 2b-3 B
3. Assessment of cardiovascular risk using national recommendation is recommended for all RA 
patients. Risk assessment should be repeated if antirheumatic therapy changes
3-4 C
4. Model of risk assessment should be adapted to RA patients by using multiplication factor of 
1.5. This multiplication factor should be used in RA patients who fulfi ll minimally 2 of 3 following 
criteria: disease duration >10 years, positive RF or anti-CCP, and having extra-articular 
manifestation
3-4 C
5. Ratio of total cholesterol/HDL should be used if SCORE model is utilized 3 C
6. Intervention should be performed based on national guideline 3 C
7. Statin, ACE-I, and/or AT-II blocker are drugs of choice 2a-3 C-D
8. Role of COX-2 inhibitor and most NSAIDs in the cardiovascular risk are not yet well-understood 
and need further investigation. Thus, physician should be thoughtful to prescribe them, especially 
in patients with CVD or having risk factors
2a-3 C
9. Use glucocorticoid with the lowest possible dose 3 C
10 Tell the patient to stop smoking 3 C
RA, rheumatoid arthritis; CVD, cardiovascular disease; RF, rheumatoid factor; SCORE, Systematic Coronary Risk Evaluation; ACE-I, 
angiotensin converting enzyme inhibitor; AT, angiotensin; COX, cyclo-oxygenase; NSAIDs, nonsteroidal anti-infl ammatory drugs
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Although pathologic mechanism of cardiovascular system 
in RA has been known widely, the treatment remains unclear. 
It is not yet known neither at what level of lipid and blood 
pressure should pharmacological therapy be started, nor 
the intervention can improve cardiovascular risk. Beside, 
although DM and RA has similar risk of CVD, it is not clear 
whether guideline for DM can reduce CVD risk signifi cantly 
in RA patients.9 It is also necessary to evaluate whether the 
drugs usually used for CVD can be used in RA patients. Type 
of drugs and its risk-benefi t is summarized in table 4.
Table 4 Type of drugs and its function for cardiovascular treatment 
in rheumatoid arthritis patients35
Focus to cardiovascular
Statin Having statistically signifi cant antiinfl ammatory activity, 
but no clinically signifi cant effect was reported
Its use should follow general recommendation for 
cardiovascular treatment  
Antihypertensive 
drugs
Its use should be based on general recommendation 
Whether ACE-I or ARB become drug of choice still 
needs further investigation
Aspirin In patients with unclear cardiovascular disease, benefi t-
risk consideration is necessary
General recommendation may help decide whether 
indication exists or not. Consider interaction with 
NSAIDs
Focus to anti-infl ammation
DMARDs Methotrexate seems to give benefi t
Lefl unomide, azathioprine, and cyclosporine may be 
related to inadequate cardiovascular outcome
TNF-α inhibitor It may reduce cardiovascular events incidence, 
especially in patients giving clinical response
Glucocorticoid It is related to higher cardiovascular morbidity and 
mortality in general population. Its role in RA treatment 
should be defi ned. Use with the lowest possible dose
NSAIDs, COX-2 
inhibitors
It is related to higher cardiovascular risk. Naproxen 
shows smallest effect making it as drug of choice
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; NSAIDs, nonsteroidal anti-infl ammatory drugs; DMARDs, disease-
modifying antirheumatic drugs; TNF, tumor necrosis factors; RA, rheumatoid 
arthritis; COX, cyclo-oxygenase
Statin
Benefi ts of statin to CVD has been proved. Statin also has 
been tested in RA patients, but there has not been large 
enough study to conclude its effect to cardiovascular 
events.35 Statin effect may be more obvious in RA patients 
because of its potency as antiinfl ammatory agent. The Trial of 
Atorvastatin in Rheumatoid Arthritis (TARA) study compared 
administration of atorvastatin 40 mg and placebo in 116 RA 
patients for six months. Signifi cant improvement of disease 
activity score (DAS) of 28 was found in atorvastatin group. 
C-reactive protein level and erythrocyte sedimentation rate 
was reduced by 50% and 28%, respectively.47 Similar study 
by El-Barbary reported decreased level of cholesterol, LDL, 
and TG; increased level of HDL; and improvement of disease 
activity parameter in atorvastatin group.48 However, number 
of subjects in these studies are too small to show therapy effect 
to cardiovascular events. Another ongoing study, The Trial 
of Atorvastatin in the Primary Prevention of Cardiovascular 
Endpoint in Rheumatoid Arthritis (TRACE RA) involving 
3,800 subjects is expected to answer this question. 
Antihypertensive drugs
Hypertension is commonly found in RA patients. Therefore, 
control of blood pressure becomes target in the management 
of RA. At present, no available data can be used to determine 
a target for blood pressure control in RA patients. Therefore, 
recommendation for general population still can be used.35 
ACE-inhibitor and AT-II blocker may give benefi cial effect 
to infl ammation and endothelial function in RA patients. 
Thus, these two agents are drug of choice for RA patients, if 
indication exists to prescribe it.46  
DMARDs
Literature has mentioned cardioprotective effect of DMARDs, 
especially MTX and biological agents. However, strategy to 
control disease activity and  progression of CVD remains 
unclear. It is not known the limit to control infl ammation in 
order to decrease cardiovascular risk and at what extent the 
therapy for RA patients can reduce cardiovascular risk.6
CONCLUSION
Higher risk of CVD has a great role to increase morbidity and 
mortality in RA patients. Evidences show this condition started 
early in disease activity. Early identifi cation and management 
of cardiovascular risk, followed by control of these factors are 
necessary to decrease cardiovascular events risk. These risk 
factors are smoking habit, physical inactivity, nutrition, body 
weight, and blood pressure. 
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